Projects / Programmes source: ARIS

Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin (Slovene)

Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   
1.04.00  Natural sciences and mathematics  Chemistry   
4.06.00  Biotechnical sciences  Biotechnology   
3.04.00  Medical sciences  Oncology   

Code Science Field
3.01  Medical and Health Sciences  Basic medicine 
Evaluation (rules)
source: COBISS
Researchers (57)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  21456  PhD Marko Anderluh  Pharmacy  Researcher  2009 - 2014  366 
2.  27588  PhD Andrej Babič  Pharmacy  Researcher  2009  19 
3.  34508  PhD Boris Brus  Pharmacy  Junior researcher  2011 - 2014  73 
4.  34510  Luka Cergol  Pharmacy  Technical associate  2011 
5.  19062  PhD Jožko Cesar  Pharmacy  Researcher  2009 - 2014  69 
6.  19281  PhD Zdenko Časar  Chemistry  Researcher  2012 - 2014  162 
7.  26498  PhD Teja Čelhar  Pharmacy  Researcher  2009 - 2010  38 
8.  31879  Petra Ferkov    Technical associate  2014 
9.  33295  PhD Anja Fic  Pharmacy  Junior researcher  2010 - 2013  10 
10.  26512  PhD Rok Frlan  Pharmacy  Researcher  2009 - 2014  111 
11.  32034  PhD Martina Gobec  Oncology  Researcher  2009 - 2014  170 
12.  15284  PhD Stanislav Gobec  Pharmacy  Researcher  2009 - 2014  824 
13.  35432  PhD Darja Gramec Skledar  Pharmacy  Junior researcher  2012 - 2014  36 
14.  33052  PhD Žiga Hodnik  Pharmacy  Researcher  2014  27 
15.  32036  PhD Martina Hrast Rambaher  Pharmacy  Beginner researcher  2009 - 2014  119 
16.  24400  PhD Janez Ilaš  Pharmacy  Researcher  2009 - 2014  240 
17.  30616  PhD Rade Injac  Pharmacy  Researcher  2011 - 2012  139 
18.  26496  PhD Žiga Jakopin  Pharmacy  Researcher  2009 - 2014  193 
19.  28220  PhD Damjan Janeš  Pharmacy  Researcher  2009 - 2014  233 
20.  21459  PhD Nataša Karas Kuželički  Pharmacy  Researcher  2009 - 2014  169 
21.  01463  PhD Danijel Kikelj  Pharmacy  Head  2009 - 2014  565 
22.  21692  Irena Klančnik Mavec    Technical associate  2012 
23.  30698  PhD Jakob Kljun  Chemistry  Researcher  2014  173 
24.  36438  PhD Damijan Knez  Pharmacy  Junior researcher  2013 - 2014  191 
25.  26495  PhD Nina Kočevar Glavač  Pharmacy  Researcher  2012 - 2014  233 
26.  32321  PhD Katra Kolšek  Pharmacy  Junior researcher  2009 - 2013  17 
27.  33908  PhD Urban Košak  Pharmacy  Junior researcher  2012 - 2014  57 
28.  27782  PhD Andreja Kovač  Pharmacy  Researcher  2009 - 2010  84 
29.  32130  PhD Boris Kramberger  Chemistry  Beginner researcher  2014  18 
30.  17436  Marija Krbavčič    Technical associate  2009 - 2012 
31.  37669  PhD Andraž Lamut  Pharmacy  Technical associate  2014  14 
32.  25491  PhD Miha Milek  Biochemistry and molecular biology  Researcher  2009 - 2011  58 
33.  12443  PhD Irena Mlinarič Raščan  Pharmacy  Researcher  2009 - 2014  528 
34.  23419  PhD Janez Mravljak  Pharmacy  Researcher  2009 - 2014  198 
35.  17437  Marjeta Mulej    Technical associate  2009 - 2014 
36.  19061  PhD Aleš Obreza  Pharmacy  Researcher  2009 - 2014  328 
37.  28861  PhD Stane Pajk  Pharmacy  Researcher  2009 - 2011  183 
38.  19317  PhD Lucija Peterlin Mašič  Pharmacy  Researcher  2009 - 2014  401 
39.  29602  PhD Matevž Prijatelj  Pharmacy  Researcher  2009 - 2012  32 
40.  32900  PhD Nataša Radić  Medical sciences  Researcher  2011  36 
41.  23549  PhD Robert Roškar  Pharmacy  Researcher  2009  299 
42.  37050  PhD Kaja Rožman  Pharmacy  Junior researcher  2014  18 
43.  08519  PhD Marija Sollner Dolenc  Pharmacy  Researcher  2009 - 2014  651 
44.  30816  PhD Izidor Sosič  Pharmacy  Researcher  2009 - 2014  246 
45.  25490  PhD Matej Sova  Pharmacy  Researcher  2009 - 2014  161 
46.  28862  PhD Roman Šink  Pharmacy  Researcher  2009 - 2014  35 
47.  29903  PhD Veronika Škedelj  Pharmacy  Researcher  2009 - 2014  29 
48.  35325  Martina Tekavec    Technical associate  2012 - 2014 
49.  28334  PhD Tihomir Tomašić  Pharmacy  Researcher  2009 - 2014  363 
50.  31492  PhD Uroš Trstenjak  Pharmacy  Junior researcher  2009 - 2012  18 
51.  29773  PhD Samo Turk  Pharmacy  Researcher  2009 - 2013  88 
52.  09635  PhD Andrej Umek  Pharmacy  Researcher  2009 - 2011  171 
53.  34512  PhD Dunja Urbančič  Pharmacy  Junior researcher  2011 - 2014  55 
54.  17438  Damijana Zalar    Technical associate  2009 - 2014 
55.  18633  PhD Anamarija Zega  Pharmacy  Researcher  2009 - 2014  184 
56.  28905  PhD Nace Zidar  Pharmacy  Researcher  2009 - 2014  215 
57.  26493  PhD Matej Živec  Pharmacy  Researcher  2009 - 2014  20 
Organisations (1)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0787  University of Ljubljana, Faculty of Pharmacy  Ljubljana  1626973  17,158 
Significance for science
Importance of the proposed research programme for the development of science resides in discovery of novel bioactive compounds with a potential for development to drugs in important therapeutic areas and in (ii) development of methods for their design, synthesis and mechanism of action studies at molecular level. In the period from 2009 till 2014 the research programme importantly contributed to discovery of innovative antibacterial agents with new mechanisms of action (MurA-F inhibitors, D-Ala-D-Ala ligase inhibitors, D-aspartate ligase inhibitors, inhibitors of transglycosylase and transpeptidase domains of penicillin-binding proteins, gyrase B and topoisomerase IV inhibitors) which is a big challenge for science worldwide due to increasing resistance of bacteria to currently used antibacterial drugs. Glycomimetic DC-SIGN receptor (lectin involved in recognition and elimination of bacteria in early infection phases) antagonists with high binding affinity in comparison to D-manose are an important contribution to discovery of novel antibacterial agents. The results obtained in DC-SIGN field offer an opportunity for establishing a spin-off company. A high worldwide incidence of cardiovascular and thrombotic diseases which is especially threatening in developed countries requests an intensive search for new antithrombotics. The research programme results in application of a concept of designed multiple ligands to discovery of novel antithrombotic agents (thrombin inhibitor/ fibrinogen receptor antagonist, factor Xa inhibitor/fibrinogen receptor antagonist) could provide the basis for antithrombotic agents of the future. Application of up to date genomic technologies, interdisciplinary approach and intensive international cooperation of the research programme enabled successful identification of new proapoptotic molecules. Understanding the mechanisms of apoptosis regulation and successful modulation of this process will pave the way to more rational design of new anticancer drugs interfering with the process of apoptosis. The identified low molecular weight 17ß-hydroxysteroid-deyidrogenase (17-HSD) and aldo-keto-reductase AKR1C1-AKR1C4 inhibitors possess a potential for further development towards drugs for treatment of hormone-dependant cancers. The developed new molecular tools for EPR spectroscopy and fluorescence microscopy/ spectroscopy are an important contribution to mechanism-of-action studies of various molecules and processes (apoptosis induction, studies of membrane domains, transmembrane signalling). The identified novel catepsin H and L inhibitors, NOD1 and NOD2 agonists and antagonists, novel modulators of voltage-gated sodium channels and PXR antagonists, inhibitors of butyrylcholine esterase – an important target involved in pathology of Alzheimer disease and FimH (adhesive receptor for carbohydrates) ligands are all important contributions to drug discovery in different therapeutic areas. The importance of results of the research programme for science in the period 2009-2014 is thus in - discovery of novel enzyme inhibitors and modulators of receptors as novel antibacterial, antithrombotic and antitumor agents with potential for further development in pharmaceutical industry - application and development of a paradigm of designed multiple ligands in the discovery of antibacterial, antithrombotic and antitumor drugs - identification of new target macromolecules involved in regulation of apoptosis and discovery of new apoptosis modulating compounds - new approaches to the design of multiple ligands - new approaches to rational drug design and drug synthesis - development of new synthetic methods - development of new mimetics of peptides, sugars and lipids - development of new molecular tools for study of biological processes and biological macromolecules
Significance for the country
Discovery of novel innovative drugs and introducing them to the market in cooperation with strategic partners is a way to assure a sustained growth to Slovenian pharmaceutical industry which is currently one of major players in the Slovenian economy. The current generic nature of the Slovenian pharmaceutical industry does not preclude its evolution into research-oriented pharmaceutical industry and education of creative and competent scientists in research programme such as this one importantly contributes to this important socio-economic task. In the period from 2009 till 2014 the research programme generated new and mastered the existing knowledge both of which are of paramount importance for sustained development of pharmaceutical industry and drug – oriented research in Slovenia. Although the major part of results of the completed research programme period can be regarded as precompetitive research results which provide valuable new knowledge on therapeutic modulation of selected drug targets involved in different pathological processes, important for development of new drugs in innovative pharmaceutical industry, some results, protected by awarded patents, have a potential of their direct application for new drug development in pharmaceutical industry on a competitive level through licensing. Novel bioactive compounds with a high potential for development to lead compounds and drugs resulting from the research programme can be a good starting point for development of innovative medicines in cooperation of the Slovenian and international pharmaceutical industry. The results related to development of alternative synthetic procedures, protected by several patent applications, find their direct application in Slovenian generic pharmaceutical industry. Several awarded national patents provide a basis for commercialization of some products of plant origin by a Slovenian private company. Some results of the research programme have reached a level of technological maturity which will enable founding of a spin-off company. Information gained on the occurrence and harmful effects of some chemicals on human health are a very important contribution to the preparation of guidelines, directives and regulations for the harmonized assessment and risk management at national and European level, which will significantly contribute to the protection of public health. Young scientists educated in the past research programme period will gain competences for autonomous creative work in pharmaceutical industry, where they will create novel research focuses. They are perfectly trained for research work at universities, other research institutes and governmental agencies. Twenty-six successfully completed doctorates mentored by the research programme team members prove this concept as one of major socio-economic achievements of the research programme in the past and are a guarantee for prosperity in the future. Fostering scientific excellence was one of major goals of the research programme, contributed to affirmation of Slovenian science through publications in leading scientific journals and participation at most important international scientific conferences worldwide. A broad network of international collaborations which are an important attribute of the research programme is a good way for promotion of Slovenian science and establishing strategic alliances for the benefit of Slovenian and global science. All these activities contribute to creation and preservation of the country's national identity in Europe and in the world. Dissemination of results of the research programme to students and general population through media as one of priority outreach activities of the research programme team contributed to popularization of science among young people and in the society.
Most important scientific results Annual report 2009, 2010, 2011, 2012, 2013, final report, complete report on dLib.si
Most important socioeconomically and culturally relevant results Annual report 2009, 2010, 2011, 2012, 2013, final report, complete report on dLib.si
Views history